RET inhibition overcomes resistance to combined CDK4/6 inhibitor and endocrine therapy in ER+ breast cancer

RET inhibition overcomes resistance to combined CDK4/6 inhibitor and endocrine therapy in ER+ breast cancer

BackgroundCombined CDK4/6 inhibitor (CDK4/6i) and endocrine therapy significantly improve the outcome of patients with advanced estrogen receptor-positive (ER+) breast cancer. However, resistance to this treatment and disease progression remains a major clinical challenge. High expression of the rec...

Full description

Saved in:

Bibliographic Details
Main Authors:	Charlotte K. Kindt, Sidse Ehmsen, Sofie Traynor, Benedetta Policastro, Nikoline Nissen, Mie K. Jakobsen, Monique F. Hundebøl, Lene E. Johansen, Martin Bak, Elsa Arbajian, Johan Staaf, Henrik J. Ditzel, Carla L. Alves
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2025-01-01
Series:	Frontiers in Oncology
Subjects:	estrogen receptor-positive breast cancer RET selpercatinib CDK4/6 inhibitor drug resistance
Online Access:	https://www.frontiersin.org/articles/10.3389/fonc.2024.1497093/full
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Mucocutaneous Adverse Events in Patients With Cancer Treated with the Highly Selective RET Kinase Inhibitor Selpercatinib (LOXO-292)
by: Rachel E. Reingold, MD, et al.
Published: (2025-03-01)

Remarkable response to low dose of selpercatinib in a patient with RET-rearranged non-small cell lung cancer
by: Jun Sakakibara-Konishi, et al.
Published: (2025-01-01)

Personalized Therapy in a Patient With EGFR-Mutated NSCLC Developing Sequential CCDC6-RET Fusion and BRAF V600E Mutation as Bypass Resistance Mechanisms
by: Arianna Marinello, MD, et al.
Published: (2025-03-01)

Real-World Outcomes of Pralsetinib in RET Fusion-Positive NSCLC
by: Francesca Lucibello, MD, et al.
Published: (2025-01-01)

Dual Inhibition of CDK4/6 and CDK7 Suppresses Triple‐Negative Breast Cancer Progression via Epigenetic Modulation of SREBP1‐Regulated Cholesterol Metabolism
by: Yilan Yang, et al.
Published: (2025-02-01)

Validation of a hypomorphic variant in CDK13 as the cause of CHDFIDD with autosomal recessive inheritance through determination of an episignature
by: Jan Fischer, et al.
Published: (2025-01-01)

Previous treatment decreases efficacy of pralsetinib in RET fusion-positive non-small-cell lung cancer
by: Lei Wang, et al.
Published: (2025-01-01)

Reticulocyte hemoglobin content: a new frontier in iron deficiency diagnostics for major surgical patients
by: Suma Choorapoikayil, et al.
Published: (2025-01-01)

Disturbance of Inorganic Phosphate Metabolism in Diabetes Mellitus: Its Relevance to the Pathogenesis of Diabetic Retinopathy
by: H. Vorum, et al.
Published: (2014-01-01)

Intratumor Genetic Heterogeneity of Breast Carcinomas as Determined by Fine Needle Aspiration and TaqMan Low Density Array
by: Maria B. Lyng, et al.
Published: (2007-01-01)

Cyclin-dependent kinase 4 and 6 inhibitors (CDK4/6i): Mechanisms of resistance and where to find them
by: L. Foffano, et al.
Published: (2025-02-01)

Diagnostic potential of CDK1 and STAT1 in acute kidney injury associated with gastrointestinal cancers: a bioinformatics-based study
by: Qiuwan Wei, et al.
Published: (2025-01-01)

Advancing treatment choices: CDK4/6 inhibitor switching in HR+/HER2- metastatic breast cancer
by: Paola Zagami, et al.
Published: (2025-02-01)

Thiazolo-pyridopyrimidines: An in silico evaluation as a lead for CDK4/6 inhibition, synthesis and cytotoxicity screening against breast cancer cell lines
by: Chaithra R Shetty, et al.
Published: (2024-07-01)

Exploring adherence in patients with advanced breast cancer: focus on CDK4/6 inhibitors
by: Baković Matea, et al.
Published: (2023-12-01)

Multitarget CDK inhibitors roscovitine and UCN‑01 induce apoptosis in colorectal cancer cells by inhibiting cell cycle progression and transcription
by: Sonal Mohan Manohar, et al.
Published: (2025-01-01)

Characteristics, treatment patterns, and biomarker testing of patients with advanced RET fusion-positive non-small cell lung cancer in a real-world multi-country observational study: a brief report
by: Urpo Kiiskinen, et al.
Published: (2025-02-01)

Biosynthesis inhibition of miR-142-5p in a N 6-methyladenosine-dependent manner induces neuropathic pain through CDK5/TRPV1 signaling
by: Jinshi Li, et al.
Published: (2025-01-01)

CDK4/6 inhibitors promote PARP1 degradation and synergize with PARP inhibitors in non-small cell lung cancer
by: Carlos M Roggero, et al.
Published: (2025-02-01)

Induction of cell cycle arrest via the p21, p27–cyclin E,A/Cdk2 pathway in SMMC-7721 hepatoma cells by clioquinol
by: Huang Zhiwei, et al.
Published: (2015-12-01)

Systematic Review and Network Meta-Analysis on Treating Hormone Receptor-Positive Metastatic Breast Cancer After CDK4/6 Inhibitors
by: Neha Pathak, et al.
Published: (2025-01-01)

High fatigue levels among psychiatric outpatients – the validity of the Danish Patient Reported Outcomes Measurement Information System Fatigue Short-Form (PROMISF-SF)
by: Ragnar Klein Olsen, et al.
Published: (2025-01-01)

The frequency of mutations in advanced thyroid cancer in Japan: a single-center study
by: Soji Toda, et al.
Published: (2024-01-01)

Applicability of a computer retinal model for scale-dependent investigation of legibility problems
by: Gábor Dömötör, et al.
Published: (2025-02-01)

Stochastic demethylation and redundant epigenetic suppressive mechanisms generate highly heterogeneous responses to pharmacological DNA methyltransferase inhibition
by: Mie K. Jakobsen, et al.
Published: (2025-01-01)

A Bibliometric Analysis of Medullary Thyroid Carcinoma From 2000 to 2022
by: TAN Meijuan, et al.
Published: (2024-07-01)

Integration of Renewable Energy Technologies in Smart Building Design for Enhanced Energy Efficiency and Self-Sufficiency
by: Ochuko Felix Orikpete, et al.
Published: (2023-11-01)

The Role Of Time Delays, Slow Processes And Chaos In Modulating The Cell-Cycle Clock
by: E.V. Presnov, et al.
Published: (2005-07-01)

Impacts of genomic alterations on the efficacy of HER2-targeted antibody–drug conjugates in patients with metastatic breast cancer
by: Riqing Huang, et al.
Published: (2025-01-01)

Outcomes in stage IIA versus stage IIB/III in the PALLAS trial [ABCSG-42/AFT-05/PrE0109/BIG-14-13])
by: A. DeMichele, et al.
Published: (2025-01-01)

State-of-the-Art Review of Emerging Trends in Renewable Energy Generation Technologies
by: Hans Tiismus, et al.
Published: (2025-01-01)

Proximal bronchiolar adenoma with malignant transformation to invasive mucinous adenocarcinoma with 4 years follow-up: a case report and literature review
by: Yuan-Hui Yang, et al.
Published: (2025-01-01)

Influence of ethnicity on cyclin-dependent kinase inhibitor efficacy and toxicity: A systematic review and meta-analysis
by: Roberto Buonaiuto, et al.
Published: (2025-02-01)

Integrated bioinformatics analysis to explore potential therapeutic targets and drugs for small cell carcinoma of the esophagus
by: Maofei Zhu, et al.
Published: (2025-01-01)

Safety of Abemaciclib in Indian Patients with Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Locally Advanced and/or Metastatic Breast Cancer: A Multicenter, Nonrandomized, Open-Label, Single-Arm, Phase 4 Study
by: Dinesh Chandra Doval, et al.

Effect of Kinases in Extracellular Vesicles from HIV-1-Infected Cells on Bystander Cells
by: Gifty A. Mensah, et al.
Published: (2025-01-01)

Modifications Caused by Enzyme-Retting and Their Effect on Composite Performance
by: Jonn A. Foulk, et al.
Published: (2011-01-01)

A BRAF V600E Mutation in RET-Negative Medullary Thyroid Cancer
by: Richard J. Robbins, et al.
Published: (2020-01-01)

Melatonin attenuates MPP+-induced autophagy via heat shock protein in the Parkinson’s disease mouse model
by: Yinli Guo, et al.
Published: (2025-01-01)

An enemy of the people.
by: Ibsen Henrik
Published: (2007)